Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Revenue (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Revenue for 15 consecutive years, with $213.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 6.72% to $213.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $912.7 million, a 5.88% increase, with the full-year FY2024 number at $854.5 million, down 7.22% from a year prior.
  • Revenue was $213.7 million for Q3 2025 at Usana Health Sciences, down from $235.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $362.3 million in Q1 2022 to a low of -$32000.0 in Q4 2022.
  • A 5-year average of $220.2 million and a median of $228.0 million in 2022 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 1653062.5% in 2022; the steepest drop was 100.01% in 2022.
  • Usana Health Sciences' Revenue stood at $274.4 million in 2021, then dropped by 16.91% to $228.0 million in 2022, then decreased by 3.02% to $221.1 million in 2023, then fell by 3.38% to $213.6 million in 2024, then increased by 0.03% to $213.7 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Revenue are $213.7 million (Q3 2025), $235.8 million (Q2 2025), and $249.5 million (Q1 2025).